Form 4: Director David E. Cohen Executes Evommune Stock Sale

Director David E. Cohen sold 6,056 shares of Evommune, Inc. common stock and received a new stock option grant.

Summary

• Director David E. Cohen sold a total of 6,056 shares of Evommune, Inc. (EVMN) common stock on June 2, 2026.
• The sales were executed in two tranches: 5,456 shares at a weighted average price of $20.21 and 600 shares at a weighted average price of $21.38.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on March 3, 2026.
• Following the sales, the director holds 17,609 shares of common stock.
• The director was also granted a new stock option for 15,673 shares with an exercise price of $19.82, vesting on the earlier of the first anniversary or the next annual meeting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions were pre-planned and represent standard portfolio management by an insider.

Positives

• The director remains a significant shareholder with 17,609 shares remaining after the sale.
• The sale was conducted via a pre-arranged Rule 10b5-1 trading plan, which is a standard mechanism for insiders to sell shares without triggering concerns regarding non-public information.

Negatives

• The filing reflects a divestment of equity by a company director.

Risks

• Future share price volatility may impact the value of the director's remaining holdings and the newly granted options.

Future Outlook

The filing does not provide specific company financial guidance, but notes that the new stock options vest on the earlier of the first anniversary of the grant or the next annual meeting of stockholders.

Management Comments

• The reporting person undertakes to provide full information regarding the number of securities sold at each separate price within the reported ranges upon request.

Industry Context

StockSavvy.ai notes that insider sales conducted under Rule 10b5-1 plans are routine corporate governance events and generally do not signal a change in company fundamentals or management sentiment.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is a standard industry practice for corporate insiders to manage liquidity while maintaining compliance with SEC regulations.

Stakeholder Impact

• Minimal impact expected as the transactions were executed under a pre-established trading plan.

Next Steps

• Vesting of the 15,673 stock options on the earlier of June 2, 2027, or the date of the next annual meeting.

Key Dates

Keywords

Evommune, EVMN, Insider Trading, Form 4, Director, Stock Option